| Fleming, Mark |
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
|
|
| Active, not recruiting | 3 | 1145 | Europe, Canada, Japan, US, RoW | 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT | Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc. | Prostatic Neoplasms | 07/25 | 02/26 | | |
|
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | AAA617, (177Lu) vipivotide tetraxetan | Novartis Pharmaceuticals | Oligometastatic Prostate Cancer (OMPC) | 12/27 | 07/30 | | |
| Recruiting | 1/2 | 144 | US | ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto | OncoC4, Inc., Prostate Cancer Clinical Trials Consortium | Metastatic Castration-resistant Prostate Cancer | 06/26 | 06/27 | | |
| Anderson, Amanda |
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
|
|
| Active, not recruiting | 3 | 1145 | Europe, Canada, Japan, US, RoW | 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT | Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc. | Prostatic Neoplasms | 07/25 | 02/26 | | |
|
NCT05417516: A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2) |
|
|
| Recruiting | 3 | 910 | Canada, RoW | Whole Breast Irradiation (WBI), Partial Breast Irradiation (PBI) | Ontario Clinical Oncology Group (OCOG) | Breast Neoplasm Female, Radiotherapy, Cosmetic Outcome | 11/29 | 11/31 | | |
| Recruiting | N/A | 60 | US | Unventilated filter cigarettes, Ventilated filter cigarettes | Masonic Cancer Center, University of Minnesota, Ohio State University, National Cancer Institute (NCI) | Tobacco Use | 02/26 | 07/26 | | |
| Recruiting | N/A | 110 | US, RoW | NEXUS Aortic Stent Graft System | Endospan Ltd. | Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer | 11/24 | 10/29 | | |
NCT06586021: Evaluation of the Aortoseal™ for Sealing and Fixation of AAA Endovascular Grafts to Aortic Wall |
|
|
| Recruiting | N/A | 25 | US | Aortoseal Endostapling System | Endoron Medical | Abdominal Aortic Aneurysm (AAA) | 09/29 | 11/29 | | |
| Recruiting | N/A | 229 | US | Neuroguard IEP Direct System | Contego Medical, Inc., Yale Cardiovascular Research Group, CardioMed Device Consultants, LLC, Advance Research Associates, iMedNet, AG Mednet | Carotid Stenosis, Carotid Artery Diseases | 06/25 | 07/25 | | |
| Recruiting | N/A | 100 | US | Nexeon Arterial Venous Allograft | LifeNet Health | End-Stage Renal Disease | 12/25 | 12/27 | | |
| Active, not recruiting | N/A | 3465 | US | Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test | Biotheranostics, Inc. | Breast Cancer | 12/28 | 12/28 | | |
| Patell, Rushad |
NCT03532139: Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) |
|
|
| Active, not recruiting | 2 | 24 | US | Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis | Beth Israel Deaconess Medical Center, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) | Ovarian Cancer | 12/23 | 05/24 | | |
NCT04339140: Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer |
|
|
| Recruiting | 2 | 30 | US | Zafirlukast, Accolate | Beth Israel Deaconess Medical Center, National Institutes of Health (NIH), National Cancer Institute (NCI), Dana-Farber Cancer Institute | Ovarian Cancer | 12/23 | 12/24 | | |
VAYHIT3, NCT05885555: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies |
|
|
| Active, not recruiting | 2 | 41 | Europe, US, RoW | Ianalumab, VAY736 | Novartis Pharmaceuticals | Primary Immune Thrombocytopenia (ITP) | 03/27 | 03/29 | | |
| Raymond, Teri |
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
|
|
| Active, not recruiting | 3 | 1145 | Europe, Canada, Japan, US, RoW | 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT | Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc. | Prostatic Neoplasms | 07/25 | 02/26 | | |
|
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | AAA617, (177Lu) vipivotide tetraxetan | Novartis Pharmaceuticals | Oligometastatic Prostate Cancer (OMPC) | 12/27 | 07/30 | | |
| Timm, Mathew |
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | AAA617, (177Lu) vipivotide tetraxetan | Novartis Pharmaceuticals | Oligometastatic Prostate Cancer (OMPC) | 12/27 | 07/30 | | |
| Phillips, Ryan |
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | AAA617, (177Lu) vipivotide tetraxetan | Novartis Pharmaceuticals | Oligometastatic Prostate Cancer (OMPC) | 12/27 | 07/30 | | |
NCT02874014: Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer |
|
|
| Active, not recruiting | 2 | 56 | US | Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes | Mayo Clinic | Prostate Cancer | 02/21 | 04/25 | | |
NCT03017794: Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy |
|
|
| Active, not recruiting | N/A | 118 | US | | Mayo Clinic | Prostate Cancer | 12/27 | 12/27 | | |
